BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cui TM, Liu Y, Wang JB, Liu LX. Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:11725-40. [PMID: 33235462 DOI: 10.2147/OTT.S279858] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Cataldi M, Manco F, Tarantino G. Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. Int J Mol Sci 2021;22:12947. [PMID: 34884762 DOI: 10.3390/ijms222312947] [Reference Citation Analysis]
2 Leone P, Solimando AG, Fasano R, Argentiero A, Malerba E, Buonavoglia A, Lupo LG, De Re V, Silvestris N, Racanelli V. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines (Basel) 2021;9:532. [PMID: 34065489 DOI: 10.3390/vaccines9050532] [Reference Citation Analysis]
3 Reinkens T, Stalke A, Huge N, Vajen B, Eilers M, Schäffer V, Dittrich-Breiholz O, Schlegelberger B, Illig T, Skawran B. Ago-RIP Sequencing Identifies New MicroRNA-449a-5p Target Genes Increasing Sorafenib Efficacy in Hepatocellular Carcinoma. J Cancer 2022;13:62-75. [PMID: 34976171 DOI: 10.7150/jca.66016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Oura K, Morishita A, Tani J, Masaki T. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Int J Mol Sci 2021;22:5801. [PMID: 34071550 DOI: 10.3390/ijms22115801] [Reference Citation Analysis]
5 Jia J, Sun J, Duan X, Li W. Clinical Values and Markers of Radiation-Induced Liver Disease for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Stereotactic Body Radiotherapy. Front Oncol 2021;11:760090. [PMID: 34970485 DOI: 10.3389/fonc.2021.760090] [Reference Citation Analysis]
6 Machairas N, Tsilimigras DI, Pawlik TM. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers 2022;14:2018. [DOI: 10.3390/cancers14082018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wang D, Sun K, Wang T, Zhang D, Sun F, Cui Y, Zhao H, Wu J. Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma. Front Pharmacol 2021;12:710943. [PMID: 34867321 DOI: 10.3389/fphar.2021.710943] [Reference Citation Analysis]
8 Pan S, Yu Y, Wang S, Tu B, Shen Y, Qiu Q, Liu X, Su N, Zuo Y, Luan J, Zhang JY, Shi M, Meng F, Wang FS. Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy. Front Immunol 2022;13:892618. [PMID: 35711409 DOI: 10.3389/fimmu.2022.892618] [Reference Citation Analysis]
9 He R, Li J, He W, Chen G, Huang Z, Li M, Wu W, Chen J, Pan Y, Jiang H, Dang Y, Yang L. Prognosis prediction ability and prospective biological mechanisms of WDHD1 in hepatocellular carcinoma tissues. Electronic Journal of Biotechnology 2022;55:78-90. [DOI: 10.1016/j.ejbt.2021.12.001] [Reference Citation Analysis]
10 Manzar GS, De BS, Abana CO, Lee SS, Javle M, Kaseb AO, Vauthey J, Tran Cao HS, Koong AC, Smith GL, Taniguchi CM, Holliday EB, Das P, Koay EJ, Ludmir EB. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers 2022;14:1901. [DOI: 10.3390/cancers14081901] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Singh A, Beechinor RJ, Huynh JC, Li D, Dayyani F, Valerin JB, Hendifar A, Gong J, Cho M. Immunotherapy Updates in Advanced Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2164. [PMID: 33946408 DOI: 10.3390/cancers13092164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Rallis KS, Makrakis D, Ziogas IA, Tsoulfas G. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World J Clin Oncol 2022; 13(6): 448-472 [DOI: 10.5306/wjco.v13.i6.448] [Reference Citation Analysis]
13 Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L. In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Front Immunol 2021;12:650486. [PMID: 34025657 DOI: 10.3389/fimmu.2021.650486] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Lyu N, Yi JZ, Zhao M. Immunotherapy in older patients with hepatocellular carcinoma. Eur J Cancer 2021;162:76-98. [PMID: 34954439 DOI: 10.1016/j.ejca.2021.11.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]